Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level - PubMed (original) (raw)

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level

Yuji Ishibashi et al. Metabolism. 2012 Aug.

Abstract

Advanced glycation end products (AGEs) and their receptor (RAGE) axis play a role in diabetic nephropathy. Statins have been shown to ameliorate renal function and reduce proteinuria in patients with chronic kidney disease. However, the effects of statin on AGEs-induced tubular cell damage remain unknown. We examined here whether and how pravastatin could block the AGEs-RAGE-elicited tubular cell injury in vitro. Gene expression level was evaluated by real-time reverse-transcription polymerase chain reactions. Reactive oxygen species (ROS) generation was measured with dihydroethidium staining. Apoptosis was analyzed in an enzyme-linked immunosorbent assay. Asymmetric dimethylarginine (ADMA) expression was evaluated by immunostaining. Pravastatin dose-dependently inhibited the AGEs-induced up-regulation of RAGE mRNA level, ROS generation and apoptosis in human renal proximal tubular cells. Further, AGEs decreased mRNA level of dimethylarginine dimethylaminohydrolase-2, an enzyme that mainly degrades asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase and subsequently increased ADMA generation in tubular cells, both of which were also prevented by pravastatin. Geranylgeranyl pyrophosphate (GGPP) treatment blocked all of the effects of pravastatin on tubular cells. We found that rosuvastatin also significantly blocked the AGEs-induced increase in RAGE mRNA level and ROS generation, both of which were prevented by GGPP. Our present study suggests that pravastatin could inhibit the AGEs-induced apoptosis and ADMA generation in tubular cells by suppressing RAGE expression probably via inhibition of GGPP synthesis. Pravastatin may exert beneficial effects on tubular damage in diabetic nephropathy by blocking the AGEs-RAGE axis.

PubMed Disclaimer

Cited by

The Role of Advanced Glycation End Products in Diabetic Vascular Complications.
Rhee SY, Kim YS. Rhee SY, et al. Diabetes Metab J. 2018 Jun;42(3):188-195. doi: 10.4093/dmj.2017.0105. Epub 2018 May 31. Diabetes Metab J. 2018. PMID: 29885110 Free PMC article. Review.
Diabetic nephropathy - complications and treatment.
Lim AKh. Lim AKh. Int J Nephrol Renovasc Dis. 2014 Oct 15;7:361-81. doi: 10.2147/IJNRD.S40172. eCollection 2014. Int J Nephrol Renovasc Dis. 2014. PMID: 25342915 Free PMC article. Review.
Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells.
Wang X, Yu S, Wang CY, Wang Y, Liu HX, Cui Y, Zhang LD. Wang X, et al. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):204-9. doi: 10.1007/s11626-014-9823-5. Epub 2014 Nov 8. In Vitro Cell Dev Biol Anim. 2015. PMID: 25381033
Advanced glycation end products and diabetic complications.
Singh VP, Bali A, Singh N, Jaggi AS. Singh VP, et al. Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13. Korean J Physiol Pharmacol. 2014. PMID: 24634591 Free PMC article. Review.
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.
Mega C, Teixeira-de-Lemos E, Fernandes R, Reis F. Mega C, et al. J Diabetes Res. 2017;2017:5164292. doi: 10.1155/2017/5164292. Epub 2017 Aug 27. J Diabetes Res. 2017. PMID: 29098166 Free PMC article. Review.

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level - PubMed (original) (raw)